Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(27%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
8
73%
Ph phase_1
2
18%
Ph phase_3
1
9%

Phase Distribution

2

Early Stage

8

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
8(72.7%)
Phase 3Large-scale testing
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

11

all time

Status Distribution
Active(6)
Completed(1)
Other(4)

Detailed Status

unknown4
Not yet recruiting3
Recruiting2
Completed1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (18.2%)
Phase 28 (72.7%)
Phase 31 (9.1%)

Trials by Status

not_yet_recruiting327%
completed19%
recruiting218%
active_not_recruiting19%
unknown436%

Recent Activity

3 active trials
Showing 5 of 11
recruitingphase_2

Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma

NCT07536789
active_not_recruitingphase_2

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

NCT05126719
not_yet_recruitingphase_2

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

NCT07331428
not_yet_recruitingphase_2

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

NCT06959108
not_yet_recruitingphase_1

MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma

NCT07054307
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07536789Phase 2

Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma

Recruiting
NCT05126719Phase 2

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Active Not Recruiting
NCT07331428Phase 2

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

Not Yet Recruiting
NCT06959108Phase 2

Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck

Not Yet Recruiting
NCT07054307Phase 1

MRG003 Plus HX008 as First-Line Treatment for EGFR-Positive Locally Advanced or Metastatic Penile Squamous Cell Carcinoma

Not Yet Recruiting
NCT04868162Phase 2

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Recruiting
NCT05751512Phase 3

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Unknown
NCT05188209Phase 2

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Unknown
NCT04838964Phase 2

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Unknown
NCT04868344Phase 1

A Study of MRG003 in Patients With Advanced Solid Tumors

Completed
NCT04838548Phase 2

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Unknown

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11